 WBA stock got hammered yesterday following the release of Q1 FY 23 results, although it clawed back some of the loss during todays market action. It is almost a cliche now, but Q1 FY 23 results really werent that bad, with WBA taking a charge of 5.7B to resolve the bulk of its opioid-epidemic litigation. 